[3][4] Approved oncology products were supplied and marketed from facilities in Farnham, Surrey, UK and Oxford, Connecticut.

Its Cellmed unit in Alzenau, Germany, was developing a drug-eluting bead product for the treatment of stroke based on proprietary stem cell technology.

They identified phosphoryl-choline (PC), a substance present in the human cell membrane, as one of the primary natural materials responsible for biocompatibility.

Biocompatibles has been publicly traded on the London Stock Exchange since 1995[6][failed verification][non-primary source needed] (LSE:BII).

Research and products are centered on the controlled and accurate delivery of drugs to patients with certain forms of cancer or vascular problems.